EMA Authorised: Lutathera (lutetium (177Lu) oxodotreotide) — Novartis Europharm Limited

View source ↗

Summary

EMA authorised Lutathera (lutetium-177 Lu oxodotreotide) for neuroendocrine tumors; orphan medicine designation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• LUTATHERA (Lutetium Lu-177 dotatate)

Snippet

Status: Authorised. Therapeutic area: Neuroendocrine Tumors. MAH: Novartis Europharm Limited. Decision date: 15/07/2026. Orphan medicine